As the United States market kicks off a holiday-shortened week with major stock indexes closing lower, investors are closely ...

After a brutal drawdown, Vertex is quietly doing the things long-term investors usually say they want and one fund just ...

General Dynamics ; Northrop Grumman ; Leidos ; Raytheon ; DRS Network & Imaging Systems (DRS); HII Mission Technologies (HII); Vertex Aerospace and L3Harris Technologies are each ...

Despite a Trump administration push, there are few facilities offering the complex treatment in the rural areas where many ...

Gemini's mini app builder uses Opal tech to deliver a new kind of Gem, and it's a game-changer for quick and simple web ...

The anti-CD40 antibody tegoprubart offers a tacrolimus-free immunosuppression option for preventing islet transplant ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

FunctionGemma is a 270M-parameter model for function calls that runs on phones and NPUs, helping teams cut cloud costs and ship faster.

According to DataM Intelligence, the global cell and gene therapy market reached a value of US$13.90 billion in 2024 and is ...